<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Tang HC</submitter><funding>National Natural Science Foundation of China</funding><pagination>1379458</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7320286</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>2020</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The role of miR-223-3p in dendritic cells (DCs) is unknown. This study is aimed at investigating the effect of miR-223-3p on the antigen uptake and presentation capacities of DCs and the underlying molecular mechanism.&lt;h4>Methods&lt;/h4>FITC-OVA antigen uptake and cell surface markers in bone marrow-derived DCs (BMDCs) were analyzed by flow cytometry. BMDCs were transfected with the miR-223-3p mimic or inhibitor. Cytokine levels were determined by ELISA. CD4+ T cell differentiation was determined by mixed lymphocyte culture assay.&lt;h4>Results&lt;/h4>OVA treatment significantly downregulated miR-223-3p in BMDCs. The miR-223-3p mimic significantly inhibited OVA-induced antigen uptake and surface expression of MHC-II on BMDCs (&lt;i>P&lt;/i> &lt; 0.01). The miR-223-3p mimic increased TGF-&lt;i>β&lt;/i>1 production in OVA-treated DCs (&lt;i>P&lt;/i> &lt; 0.01). Mixed lymphocyte reaction showed that the miR-223-3p mimic significantly promoted Treg cell differentiation. In addition, the miR-223-3p mimic significantly upregulated CD103 in DCs, indicating the promotion of tolerogenic DCs. The miR-223-3p mimic downregulated Rhob protein in OVA-induced DCs. Rhob knockdown significantly suppressed the ability of FITC-OVA endocytosis (&lt;i>P&lt;/i> &lt; 0.01) and surface MHC-II molecule expression (&lt;i>P&lt;/i> &lt; 0.01) in BMDCs, promoting promoted Treg cell differentiation. Mannose receptor (MR) knockdown significantly upregulated miR-223-3p, downregulated Rhob protein in OVA-treated DCs, inhibited the FITC-OVA endocytosis and surface MHC-II expression in BMDCs, and promoted Treg cell differentiation (all &lt;i>P&lt;/i> &lt; 0.01).&lt;h4>Conclusion&lt;/h4>These data suggest that miR-223-3p has an inhibitory effect on the antigen uptake and presentation capacities of BMDCs and promotes Treg cell differentiation, which is, at least partially, through targeting MR signaling and Rhob.</pubmed_abstract><journal>Journal of immunology research</journal><pubmed_title>miR-223-3p Inhibits Antigen Endocytosis and Presentation and Promotes the Tolerogenic Potential of Dendritic Cells through Targeting Mannose Receptor Signaling and Rhob.</pubmed_title><pmcid>PMC7320286</pmcid><funding_grant_id>U0832007</funding_grant_id><pubmed_authors>Zheng J</pubmed_authors><pubmed_authors>Tang HC</pubmed_authors><pubmed_authors>Lai YY</pubmed_authors><pubmed_authors>Xu G</pubmed_authors><pubmed_authors>Jiang HY</pubmed_authors></additional><is_claimable>false</is_claimable><name>miR-223-3p Inhibits Antigen Endocytosis and Presentation and Promotes the Tolerogenic Potential of Dendritic Cells through Targeting Mannose Receptor Signaling and Rhob.</name><description>&lt;h4>Background&lt;/h4>The role of miR-223-3p in dendritic cells (DCs) is unknown. This study is aimed at investigating the effect of miR-223-3p on the antigen uptake and presentation capacities of DCs and the underlying molecular mechanism.&lt;h4>Methods&lt;/h4>FITC-OVA antigen uptake and cell surface markers in bone marrow-derived DCs (BMDCs) were analyzed by flow cytometry. BMDCs were transfected with the miR-223-3p mimic or inhibitor. Cytokine levels were determined by ELISA. CD4+ T cell differentiation was determined by mixed lymphocyte culture assay.&lt;h4>Results&lt;/h4>OVA treatment significantly downregulated miR-223-3p in BMDCs. The miR-223-3p mimic significantly inhibited OVA-induced antigen uptake and surface expression of MHC-II on BMDCs (&lt;i>P&lt;/i> &lt; 0.01). The miR-223-3p mimic increased TGF-&lt;i>β&lt;/i>1 production in OVA-treated DCs (&lt;i>P&lt;/i> &lt; 0.01). Mixed lymphocyte reaction showed that the miR-223-3p mimic significantly promoted Treg cell differentiation. In addition, the miR-223-3p mimic significantly upregulated CD103 in DCs, indicating the promotion of tolerogenic DCs. The miR-223-3p mimic downregulated Rhob protein in OVA-induced DCs. Rhob knockdown significantly suppressed the ability of FITC-OVA endocytosis (&lt;i>P&lt;/i> &lt; 0.01) and surface MHC-II molecule expression (&lt;i>P&lt;/i> &lt; 0.01) in BMDCs, promoting promoted Treg cell differentiation. Mannose receptor (MR) knockdown significantly upregulated miR-223-3p, downregulated Rhob protein in OVA-treated DCs, inhibited the FITC-OVA endocytosis and surface MHC-II expression in BMDCs, and promoted Treg cell differentiation (all &lt;i>P&lt;/i> &lt; 0.01).&lt;h4>Conclusion&lt;/h4>These data suggest that miR-223-3p has an inhibitory effect on the antigen uptake and presentation capacities of BMDCs and promotes Treg cell differentiation, which is, at least partially, through targeting MR signaling and Rhob.</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020</publication><modification>2025-04-04T13:38:12.485Z</modification><creation>2020-11-20T08:54:12Z</creation></dates><accession>S-EPMC7320286</accession><cross_references><pubmed>32656268</pubmed><doi>10.1155/2020/1379458</doi></cross_references></HashMap>